

University of Groningen

The AGE reader

Atzeni, I M; van de Zande, S C; Westra, J; Zwerver, J; Smit, A J; Mulder, D J

Published in:
Methods

DOI:
[10.1016/j.ymeth.2021.02.016](https://doi.org/10.1016/j.ymeth.2021.02.016)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Atzeni, I. M., van de Zande, S. C., Westra, J., Zwerver, J., Smit, A. J., & Mulder, D. J. (2022). The AGE reader: a non-invasive method to assess long term tissue damage. *Methods*, 203, 533-541. <https://doi.org/10.1016/j.ymeth.2021.02.016>

Copyright


Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



The AGE Reader: A non-invasive method to assess long-term tissue damage

I.M. Atzeni^{a,*}, S.C. van de Zande^a, J. Westra^b, J. Zwerver^{c,d}, A.J. Smit^a, D.J. Mulder^a

^a Dept. of Internal Medicine, Div. of Vascular Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

^b Dept. of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

^c Center for Human Movement Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

^d Dept. of Sports Medicine, Sports Valley, Gelderse Vallei Hospital, Ede, The Netherlands

ARTICLE INFO

Keywords:

AGE Reader
Advanced glycation endproducts
Skin autofluorescence

ABSTRACT

Aims: Advanced glycation endproducts (AGEs) are sugar-modified adducts which arise during non-enzymatic glycoxidative stress. These compounds may become systemically elevated in disease states, and accumulate in tissue, especially on long-lived proteins. AGEs have been implicated in various acute, and chronic diseases, stressing the need for reliable and comprehensive measuring techniques. Measurement of AGEs in tissue such as skin requires invasive skin biopsies. The AGE Reader has been developed to assess skin autofluorescence (SAF) non-invasively using the fluorescent properties of several AGEs.

Results/conclusion: Various studies have shown that SAF is a useful marker of disease processes associated with oxidative stress. It is prospectively associated with the development of cardiovascular events in patients with diabetes, renal or cardiovascular disease, and it predicts diabetes, cardiovascular disease, and mortality in the general population. However, when measuring SAF in individual subjects, several factors may limit the reliability of the measurement. These include endogenous factors present in the skin that absorb emission light such as melanin in dark-skinned subjects, but also factors that lead to temporal changes in SAF such as acute diseases and strenuous physical exercise associated with glycoxidative stress. Also, exogenous factors could potentially influence SAF levels inadvertently such as nutrition, and for example the application of skin care products. This review will address the AGE Reader functionality and the endogenous, and exogenous factors which potentially influence the SAF assessment in individual subjects.

1. Introduction

Advanced glycation endproducts (AGEs) are sugar-modified adducts which bind to amino acids of proteins, and accumulate on proteins with a slow turnover. AGEs are formed by a process of non-enzymatic glycation and oxidation during aging.

Accumulation of AGEs has been implicated in several diseases. Plasma and tissue AGEs are higher in diseases such as diabetes mellitus [1–3], cardiovascular disease (CVD) [4,5], chronic kidney disease [6], and autoimmune diseases [7,8]. AGE levels may provide information about existing damage in chronic diseases [9,10], and measuring these levels might allow earlier identification of modifications in diseases, giving the possibility of investigating, reversing, and/or slowing down the process of accelerated aging.

The level of AGEs in the body can be measured in serum and/or plasma, however, these AGEs do not correctly reflect levels of AGEs in

tissue [11]. This is due to the high turnover rate of the large majority of proteins in the circulation in comparison to most long-lived proteins in tissue, such as collagen. To assess AGE levels in tissue, biopsies are necessary, and taking biopsies is an invasive procedure, and cannot be performed on a large scale basis. The AGE Reader (DiagnOptics Technologies BV, Groningen, The Netherlands) has been developed to non-invasively assess AGEs in human skin, as a reflection of the systemic AGE burden in individuals. This tool assesses skin autofluorescence (SAF), using the fluorescent properties that several AGEs possess. However, a number of factors exist that influence the assessment of SAF using the AGE Reader. For example, diet, smoking status, physical activity, skin type, renal function, and chronic inflammation. Therefore, both glycaemia and other factors should be taken into account when using the AGE Reader measurement in an individual; in a clinical setting, and for decisions on clinical care. This review will address the AGE Reader as a clinical tool to assess accumulation of AGEs in the skin

* Corresponding author at: Dept. of Internal Medicine, Div. of Vascular Medicine, University Medical Center Groningen, P.O. Box 30.001, 9700 RB, Groningen, The Netherlands.

E-mail address: i.m.atzeni@umcg.nl (I.M. Atzeni).

<https://doi.org/10.1016/j.ymeth.2021.02.016>

Received 12 October 2020; Received in revised form 16 December 2020; Accepted 21 February 2021

Available online 23 February 2021

1046-2023/© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

and different factors that potentially influence the assessment and interpretation.

1.1. Brief biochemistry of AGEs

The slow Maillard reaction between reducing sugars and proteins, and/or lipids is the classical mechanism of AGE formation [12]. Within a few hours, a Schiff base is formed from the interaction between carbonyl groups of reducing sugars and amino groups of proteins. More stable Amadori products are the result of intramolecular rearrangement of the Schiff base. The Amadori products undergo a slow process of oxidation which leads to reactive carbonyl compounds, precursor molecules of AGEs. Within weeks to months, this leads to the formation of AGEs [13,14]. Many different AGEs have been identified, such as pentosidine, glucosepane, N δ -(5-hydro-5-methyl-4-imidazolone-2-yl)-ornithine (MG-H1), N ϵ -carboxymethyl-lysine (CML), and N ϵ -carboxy-ethyl-lysine (CEL) [15].

Glycemic, dicarbonyl, and oxidative stress are the main drivers of AGE formation [13]. Besides the slow pathway of glycemic stress, AGEs form through a much faster pathway of ‘dicarbonyl stress’, a potentially more important route of the formation of precursor molecules of AGEs [13,16,17]. Fig. 1. Also, several exogenous sources of AGEs have been

identified, such as tobacco smoke and AGEs present in nutrition [18,19].

AGEs can be harmful by forming cross-links. Long-lived proteins, like collagen, are, due to their slow turnover, susceptible to cross-link formation [20]. Cross-links affect the function of proteins, for example, they can lead to stiffening of proteins in muscles [21], tendons [22], vascular walls [23], cartilage [24], and dermis of the skin [9,25]. In 1980, Monnier and Cerami discovered and chemically characterized the occurrence of the Maillard reaction in long-lived lens proteins [20]. Moreover, Monnier et al. found significant correlations between age-adjusted collagen-linked fluorescence (CLF) and diabetic complications [26]. AGEs also have the ability to accumulate in endothelial cells and interact with fibroblasts [27,28]. While AGEs are formed under the influence of different pathways of stress, they in turn have the potential to develop and promote oxidative stress, and to induce inflammation after binding to cell surface receptors [14,29]. The receptor for advanced glycation endproducts (RAGE) is such an example.

2. Non-invasive assessment of skin fluorescence

AGEs can be measured in blood or tissue samples using several techniques such as enzyme linked immunosorbent assay (ELISA), fluorescence spectroscopy, and fluid chromatography and gas




Fig. 1. The three different pathways leading to advanced glycation endproducts (AGEs) formation. The formation of AGEs by the Maillard reaction, lipid peroxidation, and the glycolysis pathway. ROS, reactive oxygen species. This figure has been published before and is reproduced with approval from de Vos [13].

chromatography with mass spectrometry [30,31]. However, as stated before, skin biopsies are necessary to assess long-term AGE accumulation, which is reflected in tissue. This is not feasible at study and certainly not at population level.

Skin fluorescence, emitted by several AGEs, can be measured non-invasively with different devices. CLF (excitation at 370 nm, emission at 440 nm) contributes to the fluorescence signal. Apart from the AGE Reader which we will discuss in more detail below, another device, the SCOUT (VeraLight, Inc., Albuquerque, NM, USA), also measures skin fluorescence non-invasively, referred to as skin intrinsic fluorescence (SIF). The devices differ from each other by type light and spectrum [32]. The AGE Reader SU uses a black light source with a peak wavelength of 360–370 nm for illumination and measures emission in the 420–600 nm range. The SCOUT emits light with a light emitting diode with a wavelength centered at 375 nm and fluorescence is detected at 435–655 nm [33].

Different studies have shown that skin fluorescence correlates with mean HbA1c [34,35]. This increases when HbA1c is measured over a longer period. When comparing SAF with a single measurement of HbA1c, the association with SAF is only moderate. This may depend on the short lifespan of red blood cells (8–12 weeks). Therefore, in comparison to the traditional measure HbA1c, SAF appears to be a good marker of past long-term tissue damage.

Globally, 34–47% of the variance of SAF can be statistically explained (Fig. 2) [36,37]. Age is the most important contributor, 23.8–28.5%. Other, less important contributors include lifestyle factors, such as smoking and coffee intake, explaining 3.7–8.9% and 1.6–3.6%, respectively. Physical activity, age, gender, body mass index and pack-years contributed to SAF by 25.5–35.8% in the final prediction model by van de Zande and colleagues [37]. Gender contributes less significantly, about 0.4–1.9%. Additionally, genetic factors play a role. In the LifeLines cohort by van Waateringe et al. genetic factors explained 2.1–2.7% of the variance in SAF [36]. However, the influence of heritability is probably much higher, but this has not been studied for SAF as far as we know. For example, 28% of the interindividual variation in lens protein autofluorescence was attributable to hereditary factors, in addition to environmental factors [38].

3. AGE Reader

In the late 1990-s, transcapillary leakage of sodium fluorescein in skin capillaries was assessed as a marker of endothelial dysfunction in diabetes [39,40]. It was noted that prior to intravenous injection of fluorescein and its subsequent transcapillary leakage in the dermis,




Fig. 2. Factors influencing the AGE Reader measurement. This pie-chart figure shows an overview of different factors contributing to the AGE Reader measurement in the general population. Since the percentual contribution of individual components largely depends on the population studied, these are general assumptions. For patients with chronic diseases such as diabetes and chronic kidney disease percentages will be different. For example, due to kidney dysfunction or hyperglycaemia. In addition, local skin factors and/or hypertension may play a role.

increased fluorescence of the skin was already present in patients with diabetes, especially in the dermal layer. This serendipitous finding initiated the development of dedicated equipment to address this increased SAF in diabetes patients in more detail.

In 2004, a first report showed that SAF, non-invasively assessed in the skin of the forearm, was related to AGE levels in dermal biopsies in diabetes patients and in healthy controls [25]. In these dermal biopsies, obtained from the same site on which SAF was performed, several AGEs were determined using chromatographic and mass spectrometric methods. The study pointed out that SAF reflects dermal AGE levels and could be used as a biomarker in AGE-related diseases. The device used to measure SAF was developed at the University Medical Center Groningen, The Netherlands, and was later called the AGE Reader. Although the exact individual molecular structures and the diversity of (epi) dermal tissue constituents contributing to SAF are difficult to establish, the wavelength band of the AGE Reader was chosen as such that primarily fluorescent AGEs could be assessed.

Studies using the AGE Reader confirmed that patients with diabetes indeed have higher SAF levels than control groups, especially in diabetes patients with micro- or macrovascular complications [2,16,41,42]. Subsequent studies also confirmed SAF as a predictor of complications in type 2 diabetes [41,43,44].

Because of its non-invasive character, the small size of the portable AGE Reader, and its ease to perform measurements, SAF is more suitable to evaluate the role of AGEs in large scale studies and clinical practice than the laborious biochemical assessment of AGEs in tissue biopsies and plasma samples.

3.1. Measuring SAF using the AGE Reader

The AGE Reader SU contains an UV-A lamp that emits light with a peak wavelength of 360–370 nm. Light reflected and emitted in the 300–600 nm range from the skin is measured in this research version by an inbuilt spectrometer, using an UV glass fibre (Fig. 3). In the later, more convenient version AGE Reader mu, the spectrometer was replaced by a set of photodiodes with peak sensitivities for different wavelengths, allowing the instrument to be used stand-alone and decreasing its overall size, making practical use more easy. Before every measurement with the AGE Reader SU, dark and white reference readings are performed to, respectively, correct for background light and to calculate skin reflectance. SAF is measured on the volar side of the forearm. Care should be taken to perform this measurement in an area with normal skin with minimal sunlight exposure. Initially, SAF measurements were not considered for analysis if the UV reflectance level was <10%. After introduction of more sophisticated and validated skin color correction software (version 2.3), this limit was lowered to 6%. This adaptation potentially allowed the use of SAF in a broader group of persons with darker skin color. To correct for differences in light absorption, SAF is calculated as a ratio of emitted fluorescence (420–600 nm) to reflected excitation light (300–420 nm). Consequently, SAF is expressed in arbitrary units (AU). Intra-observer variation of repeated autofluorescence measurements is 5% to 6% within one day [25].

4. Validation of the AGE Reader in skin biopsies

SAF has been proven to be a valid marker of AGE accumulation in the body. This technique has been validated in skin biopsies of patients with diabetes mellitus, hemodialysis patients, and healthy controls in several studies, as summarized in Table 1.

Studies by Meerwaldt et al. [10,25] first addressed the validity of the AGE Reader as a tool to assess AGE accumulation in non-pigmented skin. They found a significant strong correlation between SAF and AGEs in skin biopsy samples of primarily white European diabetic patients (n = 46) and age- and sex-matched non-diabetic controls (n = 46). The correlation was found between SAF and the fluorescent AGE pentosidine, and also the non-fluorescent AGEs CML and CEL. Moreover, Meerwaldt




Fig. 3. Example of normalized intensity spectra measured from the skin after excitation with UV light. The red line represents a diabetes patient. The yellow line represents a control. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

Table 1

Overview of AGE Reader validation studies and correlations between different AGEs from skin biopsies and SAF.

	N	CLF 370/440 nm	CML	Pentosidine	CEL
Meerwaldt et al. [25]	13 diabetic type 1 patients; 18 diabetic type 2 patients, and 12 control subjects	$r = 0.62^{**}$	$r = 0.55^{**}$	$r = 0.55^{**}$	$r = 0.47^{**}$
Meerwaldt et al. [9]	29 hemodialysis patients	$r = 0.71^{**}$	$r = 0.45^*$	$r = 0.75^{**}$	$r = 0.45^*$
Hu et al. [45]	5 diabetic patients; 11 arteriosclerosis obliterans patients, and 17 healthy traffic-accident victims	–	Not reported	Not reported	Not reported
Mulder et al. [47]	8 patients and 30 control subjects	$r = 0.44^*$	$r = 0.33$	$r = 0.22$	$r = 0.20$

AGEs, advanced glycation endproducts; SAF, skin autofluorescence; CLF, collagen-linked fluorescence; CML, Nε-carboxymethyl-lysine; CEL, Nε-carboxy-ethyl-lysine; *Representing a significant correlation <0.05 ; **Representing a significant correlation <0.005 .

et al. [9] found in 29 skin biopsies of hemodialysis patients a strong correlation between SAF and CLF, and pentosidine. The correlations with CML and CEL were less strong, although being significant.

A recent study by Hu et al. [45] showed in skin, artery, and nerve samples of 5 diabetic and 28 non-diabetic Chinese patients, who had encountered lower-limb amputation, that SAF was independently associated with different AGEs, including CML in skin, and pentosidine in artery and nerve. A Japanese study found that skin pentosidine content correlated significantly with SAF and bone pentosidine content. They did not find a significant correlation between SAF and pentosidine content of bone [46].

Mulder et al. showed a significant moderate correlation between SAF and CLF in 8 patients and 30 healthy young controls [47].

5. SAF as a predictor for chronic disease complications and mortality

In addition to its validity of measuring AGEs in skin, SAF has also been shown to have strong associations with clinical diseases. Over the last two decades, the number of clinical studies on SAF has increased exponentially. It has been clearly demonstrated that SAF is strongly associated with aging, and many chronic, age-related diseases in which the role of AGEs had been demonstrated using other modalities for AGE quantification. In that sense, the AGE Reader may be helpful in disease prevention, patient management, and research in large populations. Several studies suggested that SAF is useful as a predictor for cardiovascular events in patients with CVD [48,49], but also in diabetes patients [41,43,44,50], and in patients with chronic kidney disease [51–53]. Furthermore, a few studies showed that SAF is an independent

risk factor for mortality in patients with chronic kidney disease [53,54], with diabetes type 2 [32,34], and in patients with peripheral artery disease [55]. Next to predicting complications and mortality in patients, SAF is also a predictor of incident type 2 diabetes, CVD, and mortality in the general population [56].

6. Endogenous skin factors that influence SAF

During its measurement, SAF is influenced by different factors in the skin, including chromophores, fluorophores, but also by epidermal thickness, which limit the specific measurement of AGE-related signs. Furthermore, SAF should be a reflection of the systemic AGE burden, and not of local structures present in the skin. Table 2 represents different chromophores and fluorophores which may interfere with the SAF measurement [57,58].

Masters et al. [59] found that two-photon microscopy at 730 nm (equivalent to 365 nm) could penetrate in human skin to a depth down to 200 μm . Epidermal thickness is a limiting factor for wavelengths <300 nm [60]. However, Sandby-Møller et al. [61] concluded that correction for epidermal thickness, representing epidermal absorption and scattering, was negligible on SAF. In contrast, Murray et al. found that SAF was lower at the distal phalanx of the fingers especially in patients with systemic sclerosis, a site where skin thickening is the greatest in these patients [62]. Most absorption of UV-A and visible light in the epidermis is due to melanin [63]. Melanin is formed by melanocytes and is found in melanosomes. Light absorption by melanin is dependent on the amount of melanosomes in the epidermis [63]. The SAF measurement with the AGE Reader is, therefore, corrected for the reflected excitation light source.

Table 2
Overview of chromophores and fluorophores possibly interfering with SAF.

	Absorption peak (nm)	Excitation peak (nm)	Emission peak (nm)
Chromophores			
Melanin	Increases to shorter wavelengths		
Collagen	~290, ~320	325	400, 405
Elastin	~325	290, 325	340, 400
Oxyhemoglobin	412, 542, 577		
Deoxyhemoglobin	430, 555, 760		
Bilirubin	460		
Fluorophores			
CLF		328	378
Pentosidine		335	385
NADH		350	460
CLF		370	440
Keratin		370	460
Crossline		379–380	440–463
Vitamin D		390	480

SAF, skin autofluorescence; CLF, collagen-linked fluorescence.

In addition to the epidermis, in the dermis, several structural proteins and tissue constituents are present, such as collagen, elastin, and blood vessels that may interfere with the measurement of SAF. Hemoglobin, expressed in red blood cells, is also a major contributor to absorption of light in the UV-A and visible range, as integrated in the AGE Reader [57,60,64]. Moreover, the blood chromophore bilirubin seems to

play a role on SAF, but to a lesser extent [57,60].

There are also skin fluorophores that may influence SAF, like keratin, NADH, and vitamin D [57,64]. However, earlier research of our research group showed that variance in SAF could for a major part be explained by variations in the AGE pentosidine in dermal tissue of white European subjects [64].




Fig. 4. Skin autofluorescence (SAF), influencing factors, and localization of advanced glycation endproducts (AGEs). Schematic overview of the skin. This figure shows light of the AGE Reader illuminating the skin. SAF is subsequently calculated by the ratio of skin fluorescence and reflectance. Absorption of light is mainly due to the main absorbers melanin and hemoglobin. Also, the localization of AGEs is shown.

In addition, sun exposure is of importance. Sun exposure causes melanin levels to increase. This may cause absorption of fluorescent light leading to lower SAF values. Therefore, the SAF measurement is performed on the volar side of the forearm, because this location shows minimal seasonal change in pigment. Crisan et al. [27] found that AGE accumulation, e.g. CML, is higher in sun-exposed skin compared to sun-unexposed skin. However, in a previous study in white European subjects, intra-individual seasonal variance showed an Altman error of around 6%, suggesting that the effect of seasonal variance is probably limited [25]. Although a study by Meerwaldt et al. showed also that SAF measured at the volar site of the forearm and calf correlated strongly with each other ($r = 0.98$), the calf is not a practical location to assess SAF [25]. Fig. 4 shows a summary of the above mentioned components.

Less pigmented areas, such as palmoplantar sites, seem less suitable due to the thickness and variability of the epidermal layer at these skin sites. Nevertheless, Kim et al. [65] were able to assess significantly higher SAF values of palmoplantar sites in Asian patients with type 2 diabetes complications, in comparison with those without. Differences in SAF values were not observed at non-palmoplantar sites. Although they used a different set-up, their data suggest that other sites of measurement could be explored in patients with a dark skin type.

6.1. SAF and skin color

SAF can only be reliably measured in subjects with skin photo type I-IV, or reflectance values above 6% [16]. It is, therefore, important to keep skin color in mind when measuring SAF with the AGE Reader. Koetsier et al. [64] reported an algorithm to correctly measure SAF in subjects with reflectance values <12%, independent of skin color, using an additional white light in which melanin was accounted for, in addition to other relevant chromophores in the skin (hemoglobin, bilirubin), since these are accepted as main absorbers. However, the SAF measurement becomes increasingly less reliable when UV reflectance falls below 6% [66], which means that >94% of the UV light is absorbed in the skin. Possibly other fluorophores, as mentioned above, could also lead to bias. Since the exclusion of dark-skinned subjects is an important limitation, studies which extend the AGE Reader functionality to subjects with skin photo type V-VI should be encouraged.

Multiple studies have been performed to assess reference SAF values for different ethnicities. Koetsier et al. [67] provided reference values of SAF for healthy white European subjects ($n = 428$). Yue et al. [68] established reference values of SAF for the Chinese population ($n = 991$). A study by Klenovics et al. [69] established reference values of SAF in healthy subjects from Slovakia ($n = 1385$). Furthermore, Ahmad et al. [70] assessed reference values of SAF in a Saudi population ($n = 1999$).

Moreover, other studies have been performed to encounter SAF in different ethnicities, with different skin reflectance values, such as in subjects from Arabic countries, South Asia, Southeast Asia, North Africa, the East of the Mediterranean sea, and Europe [66,71]. However, it is difficult to compare these studies. This is due to several factors, such as the model of the AGE Reader used, inter-individual variances in skin type, and disturbed SAF values in subjects with reflectance values between 6 and 8%.

In conclusion, when measuring SAF with the AGE Reader, skin reflectance instead of ethnicities should be taken into account since the AGE Reader is only suitable in subjects with reflectance values >6%, or skin photo type I-IV. Given that the measurement in subjects with reflectance values <6% is still unreliable, studies encountering the AGE Reader functionality in very dark-skinned subjects should be encouraged.

6.2. Changes in SAF due to stress and physical activity

Classically, SAF measured with the AGE Reader is considered to be a reflection of AGEs that are linked to long-lived proteins accumulated over a time period of several years to decades. However, as outlined

above, SAF may also reflect the interstitial compartment of the skin and potentially its capillary network. This assumption brings into mind that SAF may also be influenced by more recent changes in AGEs. Potentially the AGE Reader could be able to measure acute rises and falls in levels of circulating AGEs, which are generally caused by oxidative stress. A cause and consequence of oxidative stress is dicarbonyl stress, leading to the formation of glyoxal and methylglyoxal [72], an example of fast formation of AGEs. The reaction of methylglyoxal with the protein arginine results in the AGE MG-H1, while CML derives from the reaction of glyoxal with lysine [73]. However, since these AGEs are not fluorescent by themselves, indirect effects of other fluorescent AGEs should be taken into account.

Acute and strenuous exercise may cause an overproduction of reactive oxygen species (ROS), which leads to higher levels of oxidative stress [74–76]. On the other hand, regular physical activity can reduce formation of ROS [74], and might, therefore, play an important role in preventing AGE accumulation. Also, acute and chronic diseases are associated with higher levels of oxidative stress [76], which plays a role in the formation of AGEs (Fig. 5). Several studies were conducted in support of this, as discussed below.

Meertens et al. [11] performed a study in ICU patients in which they found that the SAF level did not change in a period of 7 days, while plasma markers of AGEs and oxidative stress clearly increased. However, in another study, it was shown that SAF levels can fluctuate over time. Our group investigated the SAF level in ST-elevation myocardial infarction (STEMI) patients and controls [48]. STEMI patients had a significantly higher SAF level compared to controls. When SAF was measured >200 days after STEMI a significant decrease was seen in the STEMI patients, however, SAF remained higher compared to the control group. The rise in SAF might be caused by oxidative stress related to an acute STEMI. Pol et al. [77] found a significant increase of SAF after colorectal surgery, and this was related to markers of surgical stress (blood loss and duration of operation). They also assessed SAF 30 days after the surgery and showed that SAF was decreased within approximately four days to nearly the same level as before the surgery. However, SAF remained higher or even increased after the surgery when there were complications. The authors suggested that SAF might provide information of the condition of the patient before and after surgery.

Other studies investigated the relation between AGEs, instead of SAF, and physical activity over a period of time [78–82]. Almost all studies indicated that physical activity decreases AGE levels in the body. There are also cross-sectional studies that investigated the relationship between SAF or AGE levels and physical activity. Different studies found an inverse relation between physical activity and SAF [69,83–85]. These cross-sectional studies have in common that SAF decreases with increased levels of regular physical activity. On the contrary, Kellow et al. [86], Sanchez et al. [87], and Hansen et al. [88] did not find a relationship between physical activity and SAF. No studies investigated the direct effect of physical activity on SAF.

6.3. Changes in SAF due to nutrition

SAF may be directly influenced by nutritional intake of AGE-rich meals, as demonstrated in studies from the group of Vlassara [89]. Kellow et al. [86] found a positive correlation between SAF and intake of meat/meat products ($r = 0.22$). Sanchez et al. [87] reported that adherence to a Mediterranean diet was inversely associated with SAF. Moreover, cooking methods that utilise high temperature and low moisture increase the AGE content of food above the uncooked state [19]. To the best of our knowledge, no studies exist which investigate the influence of cooking methods on SAF. Although, Uribarri et al. [19] included the impact of cooking methods on AGE levels in foods. Studies on its influence on SAF should be encouraged since exogenous sources, such as coffee intake and smoking, seem to influence the SAF measurement. These are, however, effects on the long-term and the direct effect has not been studied. Stirban et al. [90] reported that SAF




Fig. 5. Schematic presentation showing a suggested increase in skin autofluorescence (SAF) caused by age and disease episodes. During a disease episode levels of oxidative stress are increased. These higher levels of oxidative stress might cause an increase in SAF in addition to the gradual influence of age. The black line represents the general increase in SAF over the years based on the article of Koetsier et al. [67]. $SAF = 0,024 * \text{age in years} + 0,83$. The dotted lines represent a trajectory with episodes of increased oxidative stress. Since the exact effect of oxidative stress on SAF is unknown, the data are created using fictional data. Oxidative stress path 1 is an example of an increased oxidative stress level for a longer period (e.g. due to diabetes). Therefore, the SAF will increase more per year compared to the general increase in SAF. As a result, the line has a steeper slope. Oxidative stress path 2 is an example of a temporary increase of oxidative stress. Thereafter, the oxidative stress level will decrease and continue with the same slope as the general increase in SAF.

increased two hours postprandially. In addition, Botros et al. [91] found that SAF was associated with coffee intake. An extensive discussion on the influence of diet on AGE levels is beyond the scope of this review.

7. Exogenous skin factors that influence SAF

The SAF measurement is influenced by different skin care products. A study by Noordzij et al. [92] showed that SAF is affected by body lotion (SAF increase of 18%), day cream (increase of >100%), sunscreen (increase of >100%), and self-browning cream (increase of >100%). Vasoconstriction, induced by a cold bath, caused a SAF increase of 10% [92]. Vasodilatation, caused by a hot bath and capsicum cream, gave a SAF decrease of, respectively, 18% and 22% [92]. SAF did not return to baseline values after cleaning with alcohol swabs and subsequent washing with soap, except for body lotion.

The effect of self-browning cream and sunscreen on SAF persisted for 2 weeks and 4 days, respectively. However, this was only assessed in three subjects [92]. This is in accordance with Ahmad et al. [70], who found in a pilot study with nine subjects that the effect of skin lotion on SAF is partially reduced (62%) by skin rinsing with soap and water. Therefore, the use of skin care products should be verified previous to performing the AGE Reader measurement. If used, dependent on the type of product, the measurement should be cancelled or postponed.

8. Conclusion

SAF has been proven to be a valid marker of AGE accumulation in the body. Various studies showed that SAF is a predictor of cardiovascular events and risk factor for mortality in patients with CVD, diabetes mellitus, chronic kidney disease, and peripheral artery disease. Importantly, SAF does also seem to be a predictor of incident type 2 diabetes, CVD, and mortality in the general population.

However, many different components exist which may influence the AGE Reader measurement. The possible influence of endogenous components and exogenous components have been discussed. Since SAF did not always return to baseline values after cleansing, use of skin care products should be taken into account.

Moreover, given that the SAF measurement is only reliable in subjects with skin reflectance values >6%, it is of importance to keep this

reflectance value in mind. To encounter the current contraindications of the SAF measurement, studies focusing on, for example, eliminating the influence of the use of creams and skin reflectance, should be encouraged.

Since the SAF measurement penetrates into the dermis, changes of plasma AGEs or their accumulation in the interstitial space may be detected, and, therefore, acute changes of AGEs may also be detected. Indeed, different situations, such as acute diseases and strenuous physical exercise, showed changes in levels of SAF. However, more research needs to be performed to better understand the role of different AGEs and SAF, and the association with different types and amounts of physical activity.

Disclosures

A.J. Smit is founder and shareholder of DiagnOptics Technologies BV, The Netherlands, manufacturing autofluorescence readers (www.diagnoptics.com).

CRediT authorship contribution statement

I.M. Atzeni: Conceptualization, Writing - original draft, Visualization. **S.C. van de Zande:** Conceptualization, Writing - original draft, Visualization. **J. Westra:** Conceptualization, Writing - review & editing, Supervision. **J. Zwerver:** Conceptualization, Writing - review & editing, Supervision. **A.J. Smit:** Conceptualization, Writing - review & editing, Supervision. **D.J. Mulder:** Conceptualization, Writing - review & editing, Supervision.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

- [1] M.J. Noordzij, J.D. Lefrandt, R. Graaff, A.J. Smit, Skin autofluorescence and glycemic variability, *Diabetes Technol. Ther.* 12 (7) (2010) 581–585.

- [2] H.L. Lutgers, R. Graaff, T.P. Links, L.J. Ubink-Veltmaat, H.J. Bilo, R.O. Gans, et al., Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes, *Diabetes Care* (2006).
- [3] V.M. Monnier, W. Sun, X. Gao, D.R. Sell, P.A. Cleary, J.M. Lachin, et al., Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes, *Cardiovasc. Diabetol.* (2015).
- [4] Kralew S, Zimmerer E, Brueckmann M, Lang S, Kalsch T, Rippert A, et al. Elevation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in patients presenting with acute myocardial infarction. *Clin Chem Lab Med* [Internet]. 2009/03/13. 2009;47(4):446–51. Available from: [internal-pdf://227.96.124.236/Kralew](https://doi.org/10.1007/s00382-009-0313-3) (2009) Elevation of the glycoxidation p.pdf.
- [5] Ikeda T, Maruyama K, Ito N, Utagawa A, Nagane M, Shikawa Y. Serum Pentosidine, An Advanced Glycation End Product, Indicates Poor Outcomes After Acute Ischemic Stroke. *J Stroke Cerebrovasc Dis* [Internet]. 21(5):386–90. Available from: [internal-pdf://0933422244/ikeda](https://doi.org/10.1089/jstroke.2012.21.386) (2012) Serum pentosidine, an advanced gl.pdf.
- [6] McIntyre NJ, Chesterton LJ, John SG, Jefferies HJ, Burton JO, Taal MW, et al. Tissue-advanced glycation end product concentration in dialysis patients. *Clin J Am Soc Nephrol* [Internet]. 2009/12/08. 2010;5(1):51–5. Available from: [internal-pdf://0772783914/McIntyre](https://doi.org/10.2202/1527-3247.1201) (2010) Tissue advanced glycation end.pdf.
- [7] C.A. Davies, A.L. Herrick, L. Cordingley, A.J. Freemont, M. Jeziorska, Expression of advanced glycation end products and their receptor in skin from patients with systemic sclerosis with and without calcinosis, *Rheumatology (Oxford)* 48 (8) (2009 Aug) 876–882.
- [8] de Groot L, Hinkema H, Westra J, Smit AJ, Kallenberg CG, Bijl M, et al. Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease. *Arthritis Res Ther* [Internet]. 2011/12/16. 2011;13(6):R205. Available from: [internal-pdf://217.125.218.150/de Groot](https://doi.org/10.1186/ar10111) (2011) Advanced glycation endproducts.pdf.
- [9] R. Meerwaldt, J.W. Hartog, R. Graaff, R.J. Huisman, T.P. Links, N.C. den Hollander, et al., Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients, *J. Am. Soc. Nephrol.* 16 (12) (2005 Dec) 3687–3693.
- [10] R. Meerwaldt, T. Links, R. Graaff, S.R. Thorpe, J.W. Baynes, J. Hartog, et al., Simple noninvasive measurement of skin autofluorescence, *Ann. N. Y. Acad. Sci.* 1043 (2005 Jun) 290–298.
- [11] J.H. Meertens, H.L. Nienhuis, J.D. Lefrandt, C.G. Schalkwijk, K. Nyyssonen, J. J. Ligtgenberg, et al., The Course of Skin and Serum Biomarkers of Advanced Glycation Endproducts and Its Association with Oxidative Stress, Inflammation, Disease Severity, and Mortality during ICU Admission in Critically Ill Patients: Results from a Prospective Pilot Study, *PLoS ONE* 11 (8) (2016 Aug 16), e0160893.
- [12] V.M. Monnier, Nonenzymatic glycosylation, the Maillard reaction and the aging process, *Journals of Gerontology* (1990).
- [13] L.C. de Vos, J.D. Lefrandt, R.P.F. Dullaart, C.J. Zeebregts, A.J. Smit, Advanced glycation end products: An emerging biomarker for adverse outcome in patients with peripheral artery disease, *Atherosclerosis*. 254 (2016 Nov) 291–299.
- [14] A. Goldin, J.A. Beckman, A.M. Schmidt, M.A. Creager, Advanced glycation end products: Sparking the development of diabetic vascular injury, *Circulation* (2006).
- [15] V.M. Monnier, D.R. Sell, Prevention and repair of protein damage by the maillard reaction in vivo. In: *Rejuvenation research*, 2006.
- [16] Mulder DJ, Water T V, Lutgers HL, Graaff R, Gans RO, Zijlstra F, et al. Skin autofluorescence, a novel marker for glycemic and oxidative stress-derived advanced glycation endproducts: an overview of current clinical studies, evidence, and limitations. *Diabetes Technol Ther.* 2006;8(5):523–35.
- [17] Miyata T, Van Ypersele De Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: Origin and significance of “carbonyl stress” in long-term uremic complications. *Kidney Int.* 1999;
- [18] C. Cerami, H. Founds, I. Nicholl, T. Mitsuhashi, D. Giordano, S. Vanpatten, et al., Tobacco smoke is a source of toxic reactive glycation products, *Proc Natl Acad Sci U S A* (1997).
- [19] J. Uribarri, S. Woodruff, S. Goodman, W. Cai, X. Chen, R. Pyzik, et al., Advanced Glycation End Products in Foods and a Practical Guide to Their Reduction in the Diet, *J. Am. Diet. Assoc.* (2010).
- [20] Monnier VM, Cerami A. Nonenzymatic browning in vivo: Possible process for aging of long-lived proteins. *Science* (80-). 1981 Jan 30;211(4481):491–3.
- [21] H. Mori, A. Kuroda, M. Ishizu, M. Ohishi, Y. Takashi, Y. Otsuka, et al., Association of accumulated advanced glycation end-products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes, *J Diabetes Investig.* (2019).
- [22] C. Couppé, R.B. Svensson, M. Kongsgaard, V. Kovanen, J.F. Grosset, O. Snorgaard, et al., Human Achilles tendon glycation and function in diabetes, *J. Appl. Physiol.* (2016).
- [23] B. Hofmann, A.C. Adam, K. Jacobs, M. Riemer, C. Erbs, H. Bushnaq, et al., Advanced glycation end product associated skin autofluorescence: a mirror of vascular function? *Exp. Gerontol.* 48 (1) (2013 Jan) 38–44.
- [24] N. Verzijl, J. DeGroot, S.R. Thorpe, R.A. Bank, J.N. Shaw, T.J. Lyons, et al., Effect of collagen turnover on the accumulation of advanced glycation end products, *J. Biol. Chem.* (2000).
- [25] R. Meerwaldt, R. Graaff, P.H. Oomen, T.P. Links, J.J. Jager, N.L. Alderson, et al., Simple non-invasive assessment of advanced glycation endproduct accumulation, *Diabetologia* 47 (7) (2004 Jul) 1324–1330.
- [26] V.M. Monnier, V. Vishwanath, K.E. Frank, C.A. Elmets, P. Dauchot, R.R. Kohn, Relation between complications of type I diabetes mellitus and collagen-linked fluorescence, *N. Engl. J. Med.* 314 (7) (1986 Feb 13) 403–408.
- [27] M. Crisan, M. Taulescu, D. Crisan, R. Cosgarea, A. Parvu, C. Cătoi, et al., Expression of Advanced Glycation End-Products on Sun-Exposed and Non-Exposed Cutaneous Sites during the Ageing Process in Humans, *PLoS ONE* (2013).
- [28] T. Kueper, T. Grune, S. Pahl, H. Lenz, V. Welge, T. Biernoth, et al., Vimentin is the specific target in skin glycation: Structural prerequisites, functional consequences, and role in skin aging, *J. Biol. Chem.* (2007).
- [29] S. Willemsen, J.W. Hartog, M.R. Heiner-Fokkema, D.J. van Veldhuisen, A.A. Voors, Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome, *Heart Fail. Rev.* 17 (2) (2012) 221–228.
- [30] M.G. van Eupen, M.T. Schram, H.M. Colhoun, J.L. Scheijen, C.D. Stehouwer, C. G. Schalkwijk, Plasma levels of advanced glycation endproducts are associated with type 1 diabetes and coronary artery calcification, *Cardiovasc Diabetol.* 12 (2013) 149.
- [31] Nagai R, Shirakawa J ichi, Ohno R ichi, Hatano K, Sugawa H, Arakawa S, et al. Antibody-based detection of advanced glycation end-products: promises vs. limitations. *Glycoconj J.* 2016;
- [32] Fokkens BT, Smit AJ. Skin fluorescence as a clinical tool for non-invasive assessment of advanced glycation and long-term complications of diabetes. *Glycoconj J.* 2016/06/12. 2016;33(4):527–35.
- [33] B. Conway, D. Edmundowicz, N. Matter, J. Maynard, T. Orchard, Skin fluorescence correlates strongly with coronary artery calcification severity in type 1 diabetes, *Diabetes Technol. Ther.* (2010).
- [34] R. Meerwaldt, H.L. Lutgers, T.P. Links, R. Graaff, J.W. Baynes, R.O.B. Gans, et al., Skin autofluorescence is a strong predictor of cardiac mortality in diabetes, *Diabetes Care* (2007).
- [35] P.A. Cleary, B.H. Braffett, T. Orchard, T.J. Lyons, J. Maynard, C. Cowie, et al., Clinical and technical factors associated with skin intrinsic fluorescence in subjects with type 1 diabetes from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study, *Diabetes Technol. Ther.* 15 (6) (2013) 466–474.
- [36] R.P. van Waateringe, S.N. Slagter, M.M. van der Klauw, J.V. van Vliet-Ostapchouk, R. Graaff, A.D. Paterson, et al., Lifestyle and clinical determinants of skin autofluorescence in a population-based cohort study, *Eur. J. Clin. Invest.* (2016).
- [37] S. Corine van de Zande, J.K. de Vries, I. van den Akker-Scheek, J. Zwerver, A. J. Smit, A physically active lifestyle is related to a lower level of skin autofluorescence in a large population with chronic-disease (LifeLines cohort), *J Sport Heal Sci.* (2020).
- [38] L. Kessel, J. Hougaard, B. Sander, K. Kyvik, T. Sørensen, M. Larsen, Lens ageing as an indicator of tissue damage associated with smoking and non-enzymatic glycation - A twin study, *Diabetologia* (2002).
- [39] J. Jager, P.H.N. Oomen, W.J. Sluiter, W.D. Reitsma, A.J. Smit, Improved Reproducibility of the ‘Large-Window’ Method of Assessing Transcapillary and Interstitial Fluorescein Diffusion in the Skin in Healthy Subjects and in Subjects with Insulin-Dependent Diabetes mellitus, *Int J Microcirc Exp.* (1997).
- [40] P.H.N. Oomen, J. Jager, K. Hoogenberg, R.P.F. Dullaart, W.D. Reitsma, A.J. Smit, Capillary permeability is increased in normo- and microalbuminuric type 1 diabetic patients: Amelioration by ACE-inhibition, *Eur. J. Clin. Invest.* (1999).
- [41] H.L. Lutgers, E.G. Gerrits, R. Graaff, T.P. Links, W.J. Sluiter, R.O. Gans, et al., Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus, *Diabetologia* 52 (5) (2009) 789–797.
- [42] A.S. Januszewski, D. Xu, Y.H. Cho, P.Z. Benitez-Aguirre, D.N. O’Neal, M.E. Craig, et al., Skin autofluorescence in people with type 1 diabetes and people without diabetes: An eight-decade cross-sectional study with evidence of accelerated aging and associations with complications, *Diabet. Med.* (2020).
- [43] M.J. Noordzij, D.J. Mulder, P.H.N. Oomen, T. Brouwer, J. Jager, M. Castro Cabezas, et al., Skin autofluorescence and risk of micro- and macrovascular complications in patients with Type2 diabetes mellitus-a multi-centre study, *Diabet. Med.* (2012).
- [44] K. Yozgatli, J.D. Lefrandt, M.J. Noordzij, P.H.N. Oomen, T. Brouwer, J. Jager, et al., Accumulation of advanced glycation end products is associated with macrovascular events and glycaemic control with microvascular complications in Type 2 diabetes mellitus, *Diabet. Med.* (2018).
- [45] H. Hu, H. Jiang, L. Zhu, X. Wu, C. Han, Accumulation of Advanced Glycation Endproducts and Subclinical Inflammation in Deep Tissues of Adult Patients With and Without Diabetes. *Can. J. Diabetes* (2018).
- [46] Y. Kida, M. Saito, A. Shinohara, S. Soshi, K. Marumo, Non-invasive skin autofluorescence, blood and urine assays of the advanced glycation end product (AGE) pentosidine as an indirect indicator of AGE content in human bone, *BMC Musculoskelet Disord* (2019).
- [47] D.J. Mulder, Skin autofluorescence in cardiovascular disease: a non-invasive approach for assessing inflammatory and oxidative stress, *Groningen* (2007) 153 p.
- [48] D.J. Mulder, P.L. van Haelst, R. Graaff, R.O. Gans, F. Zijlstra, A.J. Smit, Skin autofluorescence is elevated in acute myocardial infarction and is associated with the one-year incidence of major adverse cardiac events, *Neth Heart J.* 17 (4) (2009 Apr) 162–168.
- [49] F.R. Paolillo, V.S. Mattos, A. Borghi-Silva, V.S. Bagnato, J.C. De Castro Neto, Advanced Glycation Endproducts as Biomarkers for Risk of Diabetes and Cardiovascular Diseases by Skin Autofluorescence: A Noninvasive Optical Screening, *Photobiomodulation, Photomedicine, Laser Surg.* 2019.
- [50] A. Stirban, L. Heinemann, Skin autofluorescence - A non-invasive measurement for assessing cardiovascular risk and risk of diabetes, *Eur Endocrinol.* (2014).
- [51] D.V. Hörner, M.W. Taal, Skin autofluorescence: An emerging biomarker in persons with kidney disease, *Curr. Opin. Nephrol. Hypertens.* (2019).

- [52] N.J. McIntyre, R.J. Fluck, C.W. McIntyre, M.W. Taal, Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3, *Clin J Am Soc Nephrol* (2011).
- [53] A. Shardlow, N.J. McIntyre, N.V. Kolhe, L.B. Nellums, R.J. Fluck, C.W. McIntyre, et al., The association of skin autofluorescence with cardiovascular events and all-cause mortality in persons with chronic kidney disease stage 3: A prospective cohort study, *PLoS Med.* (2020).
- [54] S.D.S. Fraser, P.J. Roderick, N.J. McIntyre, S. Harris, C.W. McIntyre, R.J. Fluck, et al., Skin autofluorescence and all-cause mortality in stage 3 CKD, *Clin J Am Soc Nephrol* (2014).
- [55] L.C. de Vos, D.J. Mulder, A.J. Smit, R.P. Dullaart, N. Kleefstra, W.M. Lijfering, et al., Skin autofluorescence is associated with 5-year mortality and cardiovascular events in patients with peripheral artery disease, *Arterioscler. Thromb. Vasc. Biol.* 34 (4) (2014 Apr) 933–938.
- [56] R.P. van Waateringe, B.T. Fokkens, S.N. Slagter, M.M. van der Klauw, J.V. van Vliet-Ostapchouk, R. Graaff, et al., Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population, *Diabetologia* (2019).
- [57] Bachmann L, Zezell DM, Ribeiro A da C, Gomes L, Ito AS. Fluorescence spectroscopy of biological tissues - A review. *Applied Spectroscopy Reviews*. 2006.
- [58] P.J. Beisswenger, S. Howell, T. MacKenzie, H. Corstjens, N. Muizzuddin, M. S. Matsui, Two fluorescent wavelengths, 440 ex/520 em nm and 370 ex/440 em nm, reflect advanced glycation and oxidation end products in human skin without diabetes, *Diabetes Technol. Ther.* (2012).
- [59] B.R. Masters, P.T.C. So, E. Gratton, Multiphoton excitation fluorescence microscopy and spectroscopy of in vivo human skin, *Biophys. J.* (1997).
- [60] R.R. Anderson, J.A. Parrish, The optics of human skin, *J. Invest. Dermatol.* (1981).
- [61] J. Sandby-Møller, T. Poulsen, H.C. Wulf, Influence of Epidermal Thickness, Pigmentation and Redness on Skin Autofluorescence%, *Photochem. Photobiol.* (2003).
- [62] A.K. Murray, T.L. Moore, J.B. Manning, C.E.M. Griffiths, A.L. Herrick, Noninvasive measurement of skin autofluorescence is increased in patients with systemic sclerosis: an indicator of increased advanced glycation endproducts? *J. Rheumatol.* 39 (8) (2012 Aug) 1654–1658.
- [63] A. Krishnaswamy, G.V.G. Baranowski, A biophysically-based spectral model of light interaction with human skin, *Comput. Graphics Forum* (2004).
- [64] M. Koetsier, E. Nur, H. Chunmao, H.L. Lutgers, T.P. Links, A.J. Smit, et al., Skin color independent assessment of aging using skin autofluorescence, *Opt. Express* 18 (14) (2010 Jul 5) 14416–14429.
- [65] J.J. Kim, B. Jeong, Y. Cho, M.H. Kwon, Y.H. Lee, U. Kang, et al., The association between skin auto-fluorescence of palmoplantar sites and microvascular complications in Asian patients with type 2 diabetes mellitus, *Sci. Rep.* (2018).
- [66] M.J. Mook-Kanamori, M.M. Selim, A.H. Takiddin, H. Al-Homsi, K.A. Al-Mahmoud, A. Al-Obaidli, et al., Ethnic and gender differences in advanced glycation end products measured by skin auto-fluorescence, *Dermatoendocrinol.* 5 (2) (2013 Apr 1) 325–330.
- [67] M. Koetsier, H.L. Lutgers, C. de Jonge, T.P. Links, A.J. Smit, R. Graaff, Reference values of skin autofluorescence, *Diabetes Technol. Ther.* 12 (5) (2010) 399–403.
- [68] X. Yue, H. Hu, M. Koetsier, R. Graaff, C. Han, Reference values for the Chinese population of skin autofluorescence as a marker of advanced glycation end products accumulated in tissue, *Diabet. Med.* 28 (7) (2011 Jul) 818–823.
- [69] Simon Klenovics K, Kollárová R, Hodosy J, Celec P, Šebeková K, Klenovics R.: Hodosy, J.: Celec, P.: Šebeková, K. K.S. K. Reference values of skin autofluorescence as an estimation of tissue accumulation of advanced glycation end products in a general Slovak population. *Diabet Med* [Internet]. 2014;31(5):581–5. Available from: internal-pdf://0818589195/1620 Klenovics (2014).pdf.
- [70] M.S. Ahmad, Z.A. Damanhour, T. Kimhofer, H.H. Mosli, E. Holmes, A new gender-specific model for skin autofluorescence risk stratification, *Sci. Rep.* (2015).
- [71] M.S. Ahmad, T. Kimhofer, S. Ahmad, M.N. AlAma, H.H. Mosli, S.I. Hindawi, et al., Ethnicity and skin autofluorescence-based risk-engines for cardiovascular disease and diabetes mellitus, *PLoS ONE* 12 (9) (2017 Sep 20), e0185175.
- [72] Rabbani N, Thornalley PJ. Dicarbonyl stress in cell and tissue dysfunction contributing to ageing and disease. *Biochem Biophys Res Commun* [Internet]. 2015/02/11. 2015;458(2):221–6. Available from: internal-pdf://246.203.56.126/Rabbani (2015) Dicarbonyl stress in cell and t.pdf.
- [73] S. Wetzels, K. Wouters, C.G. Schalkwijk, T. Vanmierlo, J.J.A. Hendriks, Methylglyoxal-derived advanced glycation endproducts in multiple sclerosis, *Int. J. Mol. Sci.* (2017).
- [74] Pingitore A, Lima GP, Mastorci F, Quinones A, Iervasi G, Vassalle C. Exercise and oxidative stress: potential effects of antioxidant dietary strategies in sports. *Nutrition* [Internet]. 2015/06/11. 2015;31(7–8):916–22. Available from: internal-pdf://226.94.167.9/Pingitore (2015) Exercise and oxidative stress.pdf.
- [75] Finaud J, Lac G, Filaire E. Oxidative stress : relationship with exercise and training. *Sport Med.* 2006/04/01. 2006;36(4):327–58.
- [76] Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D, et al. Oxidative stress, aging, and diseases. *Clin Interv Aging* [Internet]. 2018/05/08. 2018;13:757–72. Available from: internal-pdf://84.27.235.73/Liguori (2018) Oxidative stress, aging and dis.pdf.
- [77] Pol HW, Sibma E, Zeebregts CJ, Pierik EG, Meerwaldt R. Increased skin autofluorescence after colorectal operation reflects surgical stress and postoperative outcome. *Am J Surg* [Internet]. 2011/09/06. 2011;202(5):583–9. Available from: internal-pdf://110.192.226.21/Pol (2011) Increased SAF after colorectal oper.pdf.
- [78] Bekos C, Zimmermann M, Unger L, Janik S, Hacker P, Mitterbauer A, et al. Non-professional marathon running: RAGE axis and ST2 family changes in relation to open-window effect, inflammation and renal function. *Sci Rep* [Internet]. 2016/09/23. 2016;6:32315. Available from: internal-pdf://254.147.32.139/Bekos-2016-Non-professional marathon running_.pdf.
- [79] Russell RD, Hu D, Greenaway T, Blackwood SJ, Dwyer RM, Sharman JE, et al. Skeletal Muscle Microvascular-Linked Improvements in Glycemic Control From Resistance Training in Individuals With Type 2 Diabetes. *Diabetes Care* [Internet]. 2017/07/09. 2017;40(9):1256–63. Available from: internal-pdf://248.152.198.154/Russell-2017-Skeletal muscle microvascular-lin.pdf.
- [80] Sheikholeslami-Vatani Z. D. A. Advanced Glycation End Products' Response to Resistance Training in Postmenopausal Women with Type II Diabetes. *Kinesiology* [Internet]. 2015;47(1):51–6. Available from: internal-pdf://157.19.47.12/507 Sheikholeslami-Vatani (2015).pdf.
- [81] Yoshikawa A.: Fujimoto, S. T. M. Decrease in serum levels of advanced glycation end-products by short-term lifestyle modification in non-diabetic middle-aged females. *Med Sci Monit* [Internet]. 2009;15(6):Ph65-73. Available from: internal-pdf://84.154.76.248/2568 Yoshikawa (2009).pdf.
- [82] Goon A. H.: Musalmah, M.: Anum, M. Y.: Nazaimoon, W. M.: Ngh, W. Z. JA. A. Effect of Tai Chi exercise on DNA damage, antioxidant enzymes, and oxidative stress in middle-age adults. *J Phys Act Heal* [Internet]. 2009;6(1):43–54. Available from: internal-pdf://164.13.218.73/Goon-2009-Effect of Tai Chi exercise on DNA da.pdf.
- [83] Coupe R. B.: Grosset, J. F.: Kovanen, V.: Nielsen, R. H.: Olsen, M. R.: Larsen, J. O.: Praet, S. F. E.: Skovgaard, D.: Hansen, M.: Aagaard, P.: Kjaer, M.: Magnusson, S. P. C. S. Life-long endurance running is associated with reduced glycation and mechanical stress in connective tissue. *Age (Omaha)* [Internet]. 2014;36(4). Available from: internal-pdf://217.82.57.229/Coupe-2014-Life-long endurance running is ass.pdf.
- [84] Hjerrild A.: Stausholm, M. B.: Larsen, A. E.: Josefsen, C. O.: Malmgaard-Clausen, N. M.: Dela, F.: Kjaer, M.: Magnusson, S. P.: Hansen, M.: Svensson, R. B.: Coupe, C. JN. W. Effects of Long-Term Physical Activity and Diet on Skin Glycation and Achilles Tendon Structure. *Nutrients* [Internet]. 2019;11(6). Available from: internal-pdf://0206396156/Hjerrild-2019-Effects of Long-Term Physical Ac.pdf.
- [85] Duda-Sobczak B.: Araszkiwicz, A.: Zozulinska-Ziolkiewicz, D. A. F. Association Between Self-reported Physical Activity and Skin Autofluorescence, a Marker of Tissue Accumulation of Advanced Glycation End Products in Adults With Type 1 Diabetes: A Cross-sectional Study. *Clin Ther* [Internet]. 2018;40(6):872–80. Available from: internal-pdf://141.182.120.91/Duda-Sobczak-2018-Association Between Self-rep.pdf.
- [86] Kellow M. T.: Reid, C. M. NJ. C. Association between habitual dietary and lifestyle behaviours and skin autofluorescence (SAF), a marker of tissue accumulation of advanced glycation endproducts (AGEs), in healthy adults. *Eur J Nutr* [Internet]. 2018;57(6):2209–16. Available from: internal-pdf://140.135.248.193/Kellow-2018-Association between habitual dieta.pdf.
- [87] E. Sánchez, Á. Betriu, J. Salas-Salvado, R. Pamplona, F. Barbé, F. Purroy, et al., Mediterranean diet, physical activity and subcutaneous advanced glycation end-products' accumulation: a cross-sectional analysis in the ILERVAS project, *Eur. J. Nutr.* (2020).
- [88] Hansen B.: Helge, J. W.: Johansen, N. B.: Gram, B.: Christiansen, J. S.: Brage, S.: Lauritzen, T.: Jorgensen, M. E.: Aadahl, M.: Witte, D. R. AL. C. Combined heart rate- and accelerometer-assessed physical activity energy expenditure and associations with glucose homeostasis markers in a population at high risk of developing diabetes: the ADDITION-PRO study. *Diabetes Care* [Internet]. 2013;36(10):3062–9. Available from: internal-pdf://0294149203/Hansen-2013-Combined heart rate- and accelerom.pdf.
- [89] J. Uribarri, W. Cai, O. Sandu, M. Peppas, T. Goldberg, H. Vlassara, Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. *Annals of the New York Academy of Sciences*, 2005.
- [90] A. Stirban, S. Nandrea, M. Negrea, T. Koschinsky, D. Tschöpe, Skin autofluorescence increases postprandially in human subjects, *Diabetes Technol. Ther.* (2008).
- [91] N. Botros, D. Sluik, R.P. van Waateringe, J.H.M. de Vries, A. Geelen, E.J. M. Feskens, Advanced glycation end-products (AGEs) and associations with cardio-metabolic, lifestyle, and dietary factors in a general population: the NQplus study, *Diabetes Metab. Res. Rev.* (2017).
- [92] M.J. Noordzij, J.D. Lefrandt, R. Graaff, A.J. Smit, Dermal factors influencing measurement of skin autofluorescence, *Diabetes Technol. Ther.* (2011).